MACROGENICS, INC. Debt Securities, Available-for-sale, Allowance for Credit Loss
MACROGENICS, INC. (MGNX) had Debt Securities, Available-for-sale, Allowance for Credit Loss of $0 as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Credit Losses
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss · last filed 2026-08-14
- 2026-06-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2026-03-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2025-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2025-09-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-14 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-14 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-09 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-05 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-06 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-07 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-08 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-03 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-15 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-02 |
| 2021-06-30 | $0.00 10-Q · filed 2021-07-29 |
| 2021-03-31 | $0.00 10-Q · filed 2021-04-29 |
| 2020-12-31 | $0.00 10-Q · filed 2021-11-02 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-04 |
| 2020-06-30 | $0.00 10-Q · filed 2020-07-31 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |